Altered oesophageal motility following the administration of the 5-HT1 agonist, sumatriptan

J. M. Foster, L. A. Houghton, P. J. Whorwell, J. Morris

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: The 5-HT1 agonist sumatriptan, used in the treatment of migraine, can cause chest pain. Aim: To investigate the effect of a therapeutic dose of sumatriptan (6 mg s.c.) on oesophageal motility. Methods: In 16 normal healthy subjects aged 19-32 years (9 males), the manometric response of the lower oesophageal sphincter (sleeve sensor), oesophageal body (four sites), stomach and pharynx (to register swallows) to 5 mL water swallows was assessed before and after a subcutaneous injection of either sumatriptan (6 mg) or saline control. Symptoms and ECGs were also monitored. Results: Sumatriptan 6 mg s.c. altered oesophageal motility in all subjects. This was reflected by a significant increase in the amplitude of oesophageal body contractions (change from pre- to 1 h post-injection: sumatriptan 9.9 (2.8, 17.1) mmHg vs. placebo -0.8 (-4.3, 2.6) mmHg, difference 10.8 (4.4, 17.1) mmHg; P = 0.003) and a transient increase in lower oesophageal sphincter pressure (change from pre- to 5 min post-injection: sumatriptan 10.9 (5.2, 16.6) mmHg vs. placebo 5.1 (1.8, 8.4) mmHg, difference 5.8 (-0.7, 12.3) mmHg; P = 0.08). Sumatriptan had no effect on the velocity of propagation of oesophageal contractions (change from pre- to 1 h post-injection: sumatriptan -0.1 (-0.3, 0.1) cm/s vs. placebo -0.1 (-0.3, 0.0) cm/s, difference 0.1 (-0.1, 0.2) cm/s; P = 0.40). One subject experienced chest symptoms following sumatriptan and, although motility was altered, this did not reach pathological levels. No ECG abnormalities were observed. Conclusion: Sumatriptan (6 mg s.c.) significantly alters oesophageal motor function without affecting the ECG. It is therefore possible that sumatriptan-induced chest symptoms may have an oesophageal origin. The evaluation of similar therapeutic agents for migraine on oesophageal function may be justified.

Original languageEnglish (US)
Pages (from-to)927-936
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume13
Issue number7
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Serotonin 5-HT1 Receptor Agonists
Sumatriptan
Swallows
Lower Esophageal Sphincter
Electrocardiography
Placebos
Migraine Disorders
Injections
Thorax
Therapeutic Uses
Subcutaneous Injections
Pharynx
Chest Pain
Stomach
Healthy Volunteers

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Altered oesophageal motility following the administration of the 5-HT1 agonist, sumatriptan. / Foster, J. M.; Houghton, L. A.; Whorwell, P. J.; Morris, J.

In: Alimentary Pharmacology and Therapeutics, Vol. 13, No. 7, 1999, p. 927-936.

Research output: Contribution to journalArticle

Foster, J. M. ; Houghton, L. A. ; Whorwell, P. J. ; Morris, J. / Altered oesophageal motility following the administration of the 5-HT1 agonist, sumatriptan. In: Alimentary Pharmacology and Therapeutics. 1999 ; Vol. 13, No. 7. pp. 927-936.
@article{79ec189e4e0f4df295220b77915f18da,
title = "Altered oesophageal motility following the administration of the 5-HT1 agonist, sumatriptan",
abstract = "Background: The 5-HT1 agonist sumatriptan, used in the treatment of migraine, can cause chest pain. Aim: To investigate the effect of a therapeutic dose of sumatriptan (6 mg s.c.) on oesophageal motility. Methods: In 16 normal healthy subjects aged 19-32 years (9 males), the manometric response of the lower oesophageal sphincter (sleeve sensor), oesophageal body (four sites), stomach and pharynx (to register swallows) to 5 mL water swallows was assessed before and after a subcutaneous injection of either sumatriptan (6 mg) or saline control. Symptoms and ECGs were also monitored. Results: Sumatriptan 6 mg s.c. altered oesophageal motility in all subjects. This was reflected by a significant increase in the amplitude of oesophageal body contractions (change from pre- to 1 h post-injection: sumatriptan 9.9 (2.8, 17.1) mmHg vs. placebo -0.8 (-4.3, 2.6) mmHg, difference 10.8 (4.4, 17.1) mmHg; P = 0.003) and a transient increase in lower oesophageal sphincter pressure (change from pre- to 5 min post-injection: sumatriptan 10.9 (5.2, 16.6) mmHg vs. placebo 5.1 (1.8, 8.4) mmHg, difference 5.8 (-0.7, 12.3) mmHg; P = 0.08). Sumatriptan had no effect on the velocity of propagation of oesophageal contractions (change from pre- to 1 h post-injection: sumatriptan -0.1 (-0.3, 0.1) cm/s vs. placebo -0.1 (-0.3, 0.0) cm/s, difference 0.1 (-0.1, 0.2) cm/s; P = 0.40). One subject experienced chest symptoms following sumatriptan and, although motility was altered, this did not reach pathological levels. No ECG abnormalities were observed. Conclusion: Sumatriptan (6 mg s.c.) significantly alters oesophageal motor function without affecting the ECG. It is therefore possible that sumatriptan-induced chest symptoms may have an oesophageal origin. The evaluation of similar therapeutic agents for migraine on oesophageal function may be justified.",
author = "Foster, {J. M.} and Houghton, {L. A.} and Whorwell, {P. J.} and J. Morris",
year = "1999",
doi = "10.1046/j.1365-2036.1999.00518.x",
language = "English (US)",
volume = "13",
pages = "927--936",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Altered oesophageal motility following the administration of the 5-HT1 agonist, sumatriptan

AU - Foster, J. M.

AU - Houghton, L. A.

AU - Whorwell, P. J.

AU - Morris, J.

PY - 1999

Y1 - 1999

N2 - Background: The 5-HT1 agonist sumatriptan, used in the treatment of migraine, can cause chest pain. Aim: To investigate the effect of a therapeutic dose of sumatriptan (6 mg s.c.) on oesophageal motility. Methods: In 16 normal healthy subjects aged 19-32 years (9 males), the manometric response of the lower oesophageal sphincter (sleeve sensor), oesophageal body (four sites), stomach and pharynx (to register swallows) to 5 mL water swallows was assessed before and after a subcutaneous injection of either sumatriptan (6 mg) or saline control. Symptoms and ECGs were also monitored. Results: Sumatriptan 6 mg s.c. altered oesophageal motility in all subjects. This was reflected by a significant increase in the amplitude of oesophageal body contractions (change from pre- to 1 h post-injection: sumatriptan 9.9 (2.8, 17.1) mmHg vs. placebo -0.8 (-4.3, 2.6) mmHg, difference 10.8 (4.4, 17.1) mmHg; P = 0.003) and a transient increase in lower oesophageal sphincter pressure (change from pre- to 5 min post-injection: sumatriptan 10.9 (5.2, 16.6) mmHg vs. placebo 5.1 (1.8, 8.4) mmHg, difference 5.8 (-0.7, 12.3) mmHg; P = 0.08). Sumatriptan had no effect on the velocity of propagation of oesophageal contractions (change from pre- to 1 h post-injection: sumatriptan -0.1 (-0.3, 0.1) cm/s vs. placebo -0.1 (-0.3, 0.0) cm/s, difference 0.1 (-0.1, 0.2) cm/s; P = 0.40). One subject experienced chest symptoms following sumatriptan and, although motility was altered, this did not reach pathological levels. No ECG abnormalities were observed. Conclusion: Sumatriptan (6 mg s.c.) significantly alters oesophageal motor function without affecting the ECG. It is therefore possible that sumatriptan-induced chest symptoms may have an oesophageal origin. The evaluation of similar therapeutic agents for migraine on oesophageal function may be justified.

AB - Background: The 5-HT1 agonist sumatriptan, used in the treatment of migraine, can cause chest pain. Aim: To investigate the effect of a therapeutic dose of sumatriptan (6 mg s.c.) on oesophageal motility. Methods: In 16 normal healthy subjects aged 19-32 years (9 males), the manometric response of the lower oesophageal sphincter (sleeve sensor), oesophageal body (four sites), stomach and pharynx (to register swallows) to 5 mL water swallows was assessed before and after a subcutaneous injection of either sumatriptan (6 mg) or saline control. Symptoms and ECGs were also monitored. Results: Sumatriptan 6 mg s.c. altered oesophageal motility in all subjects. This was reflected by a significant increase in the amplitude of oesophageal body contractions (change from pre- to 1 h post-injection: sumatriptan 9.9 (2.8, 17.1) mmHg vs. placebo -0.8 (-4.3, 2.6) mmHg, difference 10.8 (4.4, 17.1) mmHg; P = 0.003) and a transient increase in lower oesophageal sphincter pressure (change from pre- to 5 min post-injection: sumatriptan 10.9 (5.2, 16.6) mmHg vs. placebo 5.1 (1.8, 8.4) mmHg, difference 5.8 (-0.7, 12.3) mmHg; P = 0.08). Sumatriptan had no effect on the velocity of propagation of oesophageal contractions (change from pre- to 1 h post-injection: sumatriptan -0.1 (-0.3, 0.1) cm/s vs. placebo -0.1 (-0.3, 0.0) cm/s, difference 0.1 (-0.1, 0.2) cm/s; P = 0.40). One subject experienced chest symptoms following sumatriptan and, although motility was altered, this did not reach pathological levels. No ECG abnormalities were observed. Conclusion: Sumatriptan (6 mg s.c.) significantly alters oesophageal motor function without affecting the ECG. It is therefore possible that sumatriptan-induced chest symptoms may have an oesophageal origin. The evaluation of similar therapeutic agents for migraine on oesophageal function may be justified.

UR - http://www.scopus.com/inward/record.url?scp=0033036670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033036670&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.1999.00518.x

DO - 10.1046/j.1365-2036.1999.00518.x

M3 - Article

VL - 13

SP - 927

EP - 936

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 7

ER -